**1. Introduction**

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 23 million people and has caused more than 800,000 deaths worldwide as of August 23, 2020 (https://coronavirus.jhu.edu/map.html). SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a host cell receptor to infect humans [@b0005], [@b0010], [@b0015], [@b0020]. ACE2 plays an important role in regulating cardiovascular and renal function [@b0025]. This protein has recently received extensive attention for its role in SARS-CoV-2 infection [@b0005], [@b0010], [@b0020]. Our recent study revealed that ACE2 is expressed in various human tissues [@b0030], suggesting that SARS-CoV-2 may invade various human organs besides the lungs. Moreover, SARS-CoV-2 infection may result in ACE2 upregulation [@b0035]. However, ACE2 deficiency may exacerbate outcomes in patients with SARS-CoV-2 infection [@b0040]. Indeed, a recent study showed that ACE2 was downregulated in virus-infected lung tissue [@b0045], indicating a potential protective role of ACE2 in patients with SARS-CoV-2 infection. ACE2 also plays a protective role in hypertension and heart disease [@b0040].

Many studies have investigated the association between ACE2 and cancer [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090]. For example, Yu-Jun et al. analyzed ACE2 expression in various cancers and revealed a positive association between ACE2 expression and survival prognosis in liver cancer [@b0050]. Cai et al. described the genetic alteration, mRNA expression, and DNA methylation of ACE2 in over 30 cancer types and revealed genetic and epigenetic variations of ACE2 in various cancers [@b0055]. Several studies demonstrated that ACE2 had antitumor effects by inhibiting tumor angiogenesis [@b0065], [@b0070], [@b0080]. Zhang et al. revealed that *ACE2* expression was more highly expressed in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) than in normal tissues [@b0085]. Huang et al. found that ACE2 expression had a significant association with immune cell infiltration in various normal and cancer tissues [@b0090]. A recent study [@b0045] showed that ACE2 expression was associated with increased tumor immune infiltration and was a positive prognostic factor in uterine corpus endometrial and renal papillary cell cancers. Despite these previous studies, a systemic investigation into the association between ACE2 expression and antitumor immunity, oncogenic pathways, tumor progression phenotypes, and clinical outcomes in pan-cancer remains lacking.

In this study, we investigated associations between *ACE2* expression and antitumor immune signatures in 13 human cancer cohorts from the Cancer Genome Atlas (TCGA) program (https://cancergenome.nih.gov/). We also explored associations between *ACE2* expression and multiple tumor phenotypes, including cell proliferation, stemness, epithelial-mesenchymal transition (EMT), oncogenic signaling, and clinical outcomes in these cancer cohorts. We also investigated the association between *ACE2* expression and immunotherapy response in four cancer cohorts receiving the immune checkpoint blockade therapy. This study aimed to provide new insights into the association between ACE2 and cancer and the potential association between cancer and SARS-CoV-2 infection.

**2. Material and methods**

0.1. Datasets {#s0005}
=============

From the genomic data commons data portal (https://portal.gdc.cancer.gov/), we obtained RNA-Seq gene expression profiling datasets (level 3 and RSEM normalized) for 13 TCGA cancer cohorts. The 13 cancer cohorts included cervical squamous-cell carcinoma (CESC), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal clear cell carcinoma (KIRP), LUAD, LUSC, skin cutaneous melanoma (SKCM), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), ovarian carcinoma (OV), and pancreatic adenocarcinoma (PAAD). We log2-transformed all RSEM-normalized gene expression values before further analyses. Besides, we obtained gene expression profiling and clinical data in four cancer cohorts receiving anti-PD-1/PD-L1/CTLA-4 immunotherapy from their related publications, including Nathanson (melanoma) [@b0095], Topalian (melanoma) [@b0100],Ascierto (renal cell carcinoma) [@b0105], and Snyder (bladder cancer) cohorts [@b0110]. A summary of these datasets is presented in Supplementary Table S1.

0.2. Evaluating the enrichment levels of immune signatures, pathways, and tumor phenotypes {#s0010}
==========================================================================================

We evaluated the enrichment level of a pathway or tumor phenotype in a tumor sample by the single-sample gene-set enrichment analysis (ssGSEA) score [@b0115]. The gene set included all marker genes of a pathway or tumor phenotype. A total of six cancer-associated pathways (cell cycle, mismatch repair, TGF-β, Wnt, VEGF, and Notch signaling) and three tumor phenotypes (cell proliferation, stemness, and EMT) were analyzed. We presented the marker genes of these pathways and tumor phenotypes in Supplementary Table S2.

0.3. Gene-set enrichment analysis {#s0015}
=================================

We defined high-*ACE2*-expression-level (upper third) and low-*ACE2*-expression-level (bottom third) tumors in each cancer type based on *ACE2* expression profiles. We identified the KEGG [@b0120] pathways highly enriched in both groups of tumors using GSEA [@b0125] with a threshold of adjusted *p*-value \< 0.05. Moreover, we used WGCNA [@b0130] to detect the gene modules (gene ontology) differentially enriched between the high- and low-*ACE2*-expression-level tumors in pan-cancer. We identified the hub genes as the genes connected to at least 5 other genes with a connectedness weight greater than 0.25 in a gene module and built their co-expression network.

0.4. Statistical analysis {#s0020}
=========================

We used Spearman's correlation test to evaluate the correlation (*ρ*) of *ACE2* expression levels with the enrichment levels of pathways or tumor phenotypes, which were not normally distributed. We used Pearson\'s correlation test to evaluate the correlation (*r*) of *ACE2* expression levels with the ratios of immune signatures, which was the log2-transformed values of the ratios between the mean expression levels of all marker genes in immune signatures and was normally distributed. We used the Benjamini and Hochberg method [@b0135] to calculate the FDR for adjusting for multiple tests. We compared overall survival (OS), disease-specific survival (DSS), progression-free interval (PFI), and disease-free interval (DFI) between the high- and low-*ACE2*-expression-level tumors. We utilized Kaplan-Meier curves to display survival time differences and the log-rank test to evaluate the significance of survival time differences. The R package "survival" was used to perform the survival analyses.

**3. Results**

0.5. Association of *ACE2* expression with immune signatures and immunotherapy response in cancer {#s0025}
=================================================================================================

GSEA [@b0125] identified many immune-related pathways highly enriched in the high-*ACE2*-expression-level tumors at least 5 cancer types. These pathways included viral myocarditis, T cell receptor signaling, systemic lupus erythematosus, primary immunodeficiency, NOD-like receptor signaling, natural killer cell-mediated cytotoxicity, Leishmania infection, Jak-STAT signaling, intestinal immune network for IgA production, hematopoietic cell lineage, graft-versus-host disease, Fc epsilon RI signaling, epithelial cell signaling in Helicobacter pylori infection, cytosolic DNA-sensing, cytokine-cytokine receptor interaction, chemokine signaling, B cell receptor signaling, autoimmune thyroid disease, asthma, antigen processing and presentation, and allograft rejection ([Fig. 1](#f0005){ref-type="fig"} A). Moreover, we found that *ACE2* expression levels positively correlated with the immune-promoting/immune-inhibiting ratios in pan-cancer (Pearson's correlation test, *r* = 0.25, *p* = 2.37 × 10^-71^) and in 12 individual cancer types (adjusted *p*-value (FDR) \< 0.05) ([Fig. 1](#f0005){ref-type="fig"}B). This suggests that *ACE2* expression has a stronger positive association with the immune-promoting signature than the immune-inhibiting signature in these cancer types. Altogether, these results suggest a prominent positive association between *ACE2* expression and antitumor immune signatures in cancer. We found that *ACE2* had a positive expression correlation with *PD-L1* in pan-cancer and in 6 individual cancer types (FDR \< 0.05) ([Fig. 1](#f0005){ref-type="fig"}C). We expected that the *ACE2* expression would have a positive association with the response to anti-PD-1/PD-L1/CTLA-4 immunotherapy. We confirmed the anticipation in four cancer cohorts receiving immune checkpoint blockade therapy. In these cohorts, the high-*ACE2*-expression-level (\> median) tumors displayed a higher rate of immunotherapy response than the low-*ACE2*-expression-level (\< median) tumors (67% versus 17%, 80% versus 40%, 40% versus 20%, and 46% versus 25% for Nathanson (melanoma), Topalian (melanoma), Ascierto (renal cell carcinoma), and Snyder (bladder cancer) cohorts, respectively) ([Fig. 1](#f0005){ref-type="fig"}D). As a result, the former had better overall survival (OS) than the latter in the Nathanson cohort, which had related data available (log-rank test, *p* = 0.036) ([Fig. 1](#f0005){ref-type="fig"}E). These results suggest that the *ACE2* expression is likely to be a positive predictor for anti-PD-1/PD-L1 immunotherapy.Fig. 1**Association of *ACE2* expression with immune signatures and immunotherapy response in cancer. A**. Immune-related pathways upregulated in high- (upper third) versus low-*ACE2*-expression-level (bottom third) tumors in at least 5 cancer types identified by GSEA [@b0125] (adjusted *p*-value (FDR) \< 0.05). **B**. Significant positive correlations of *ACE2* expression levels with the ratios of immune-promoting/immune-inhibiting cytokines in pan-cancer and in 12 individual cancer types. The Pearson correlation coefficient (*r*) and *p-* or FDR-value are shown. **C**. The positive expression correlation between *ACE2* and *PD-L1* in pan-cancer and in 6 individual cancer types. **D**. Higher rate of immunotherapy response in the high-*ACE2*-expression-level (\> median) than in the low-*ACE2*-expression-level (\< median) tumors in four cancer cohorts receiving immune checkpoint blockade therapy. **E**. Kaplan-Meier survival curves showing better survival in high-*ACE2*-expression-level (\> median) than in low-*ACE2*-expression-level (\< median) cancer patients with immune checkpoint blockade therapy. The log-rank test *p*-value is shown. **F**. Correlations between pathway activity and PD-L1 expression levels in pan-cancer and in 13 individual cancer types. The Spearman correlation coefficient (*ρ*) and FDR-value are shown. FDR: false discovery rate. \* FDR \< 0.05; \*\* FDR \< 0.01; \*\*\* FDR \< 0.001; ns: not significant. They also apply to the following figures.

GSEA [@b0125] also identified several cancer-associated pathways highly enriched in the high-*ACE2*-expression-level tumors at least 5 cancer types. These pathways included axon guidance, renin angiotensin system, PPAR signaling, MAPK signaling, glycolysis, cell adhesion molecules, endocytosis, and calcium signaling. We found that the activities of these pathways were significantly and positively associated with *PD-L1* expression levels in pan-cancer (FDR \< 0.001) ([Fig. 1](#f0005){ref-type="fig"}F). In individual cancer types, the elevated activities of these pathways were also likely to correlate with increased *PD-L1* expression levels (FDR \< 0.05) ([Fig. 1](#f0005){ref-type="fig"}F). The elevated activities of these pathways could be responsible for the more active immunotherapy response in cancer.

0.6. Association of *ACE2* expression with oncogenic pathways and tumor phenotypes in cancer {#s0030}
============================================================================================

We quantified the activity of a pathway using the single-sample gene-set enrichment analysis (ssGSEA) [@b0115] score of the set of genes included in the pathway. We found that *ACE2* expression levels inversely correlated with the activity of cell cycle, mismatch repair, TGF-β, Wnt, VEGF, and Notch signaling pathways in 10, 7, 9, 7, 5, and 7 individual cancer types, respectively (Spearman's correlation test, FDR \< 0.05) ([Fig. 2](#f0010){ref-type="fig"} A). Moreover, we found that *ACE2* expression levels had a significant inverse correlation with the expression levels of *M*KI67, which is a tumor proliferation index marker, in pan-cancer and 8 individual cancer types (Pearson's correlation test, FDR \< 0.05) ([Fig. 2](#f0010){ref-type="fig"}B). Tumor stemness represents a stem cell-like tumor phenotype associated with tumor progression, metastasis, immune evasion, and drug resistance. We found that *ACE2* expression levels showed a marked negative correlation with tumor stemness scores (ssGSEA scores) in pan-cancer and in 10 individual cancer types (FDR \< 0.05) ([Fig. 2](#f0010){ref-type="fig"}C). EMT plays an outstanding role in facilitating malignant transformation, tumor progression, and metastasis. We observed a marked negative correlation between *ACE2* expression levels and EMT signature scores (ssGSEA scores) in 11 individual cancer types (FDR \< 0.05) ([Fig. 2](#f0010){ref-type="fig"}D). Overall, these data indicate that ACE2 could be a protective factor for cancer progression. Indeed, survival analyses showed that *ACE2* upregulation was associated with favorable survival in pan-cancer (log-rank test, *p* \< 0.01 for OS, DSS, PFI, and DFI) and in KIRC, KIRP, LUSC, and OV (log-rank test, *p* \< 0.05 for OS, DSS, PFI, and/or DFI) ([Fig. 2](#f0010){ref-type="fig"}E). Furthermore, we found that *ACE2* expression levels significantly decreased with the tumor advancement in KIRC (two-sided Student's *t* test, *p* \< 0.01, fold change \> 1.5 for high-grade (G3-4) versus low-grade (G1-2), late-stage (stage III-IV) versus early-stage (stage I-II), large tumor size (T3-4) versus small tumor size (T1-2), without regional lymph nodes (N0) versus with lymph nodes (N1-3), and no metastasis (M0) versus metastasis (M1)) ([Fig. 2](#f0010){ref-type="fig"}F).Fig. 2**Association of *ACE2* expression with oncogenic pathways and tumor phenotypes in cancer.***ACE2* expression levels are likely to inversely correlate with the activity of oncogenic pathways (**A**), *M*KI67 expression levels (**B**), stemness scores (**C**), and EMT signature scores (**D**) in cancer. EMT: epithelial-mesenchymal transition; **E**. Kaplan-Meier survival curves showing that *ACE2* upregulation is associated with favorable survival in pan-cancer and multiple individual cancer types. Log-rank test *p*-values are shown. OS: overall survival; DSS: disease-specific survival; PFI: progression-free interval; DFI: disease-free interval. **F**. *ACE2* expression levels significantly increase with tumor advancement in KIRC. KIRC: kidney renal clear cell carcinoma.

0.7. Identifying interaction networks of ACE2 in cancer {#s0035}
=======================================================

We identified 217 and 26 genes having marked positive and negative expression correlations with *ACE2* in pan-cancer, respectively (\|*r*\| \> 0.5) ([Fig. 3](#f0015){ref-type="fig"} A and Supplementary Table S3). WGCNA [@b0130] identified five gene modules (indicated in blue, green, yellow, brown, and turquoise color, respectively) highly enriched in the high-*ACE2*-expression-level tumors and three gene modules (indicated in pink, black, and red color, respectively) highly enriched in the low-*ACE2*-expression-level tumors ([Fig. 3](#f0015){ref-type="fig"}B). The GO terms highly enriched in the high-*ACE2*-expression-level tumors mainly included brush border, cellular response to zinc ion, cell adhesion, immune response, and chemical homeostasis within a tissue. In contrast, the GO terms highly enriched in the low-*ACE2*-expression-level tumors mainly included microtubule-based process, cell cycle, and nucleic acid binding ([Fig. 3](#f0015){ref-type="fig"}B). Again, these results indicate that *ACE2* expression has a significant positive association with antitumor immune response and a significant negative association with the cell cycle in cancer, suggesting the potential protective role of ACE2 from cancer progression.Fig. 3**Interaction networks of ACE2 in cancer. A**. 217 and 26 genes having marked positive and negative expression correlations with *ACE2* in pan-cancer, respectively (\|*r*\| \> 0.5). The size of nodes is proportional to the absolute values of the expression correlation coefficients. **B**. Gene modules (gene ontology) enriched in high-*ACE2*-expression-level and low-*ACE2*-expression-level pan-cancer. **C**. Co-expression subnetwork of the immune response module (in brown) enriched in high-*ACE2*-expression-level pan-cancer centered on three transcription factor genes (*EOMES*, *IRF4*, and *TBX21*).

From the brown gene module, we identified 82 hub genes mainly associated with immune-related pathways. Among the 82 hub genes, three transcription factor (TF) genes, including *EOMES*, *IRF4*, and *TBX21*, were co-expressed with many other immune-related genes, such as *PDCD1*, *TIGIT*, *GZMK*, *IL21R*, and *PRF1* ([Fig. 3](#f0015){ref-type="fig"}C). The association between these TFs and immune regulation has been well recognized, such as EOMES (Eomesodermin) mediating the CD8^+^ T cell differentiation [@b0140], IRF4 (interferon regulatory factor 4) regulating immune cell development [@b0145], and TBX21 (T-bet) playing a pivotal role in regulating Th1 cell development [@b0150].

1. Discussion {#s0040}
-------------

We investigated the association of *ACE2* expression with immune signatures, oncogenic pathways, and tumor phenotypes in diverse cancer cohorts. Our results indicate that ACE2 is a potential protective factor for cancer progression. In particular, the ACE2 downregulation correlates with worse survival and tumor advancement in KIRC, also known as clear cell renal cell carcinoma (ccRCC). Previous studies demonstrated that ACE2 exerts antitumor effects by inhibiting tumor angiogenesis [@b0065] and promoting tumor immune infiltration [@b0045]. Our results are consistent with these previous findings. Besides, we found that ACE2 upregulation was associated with reduced cell proliferation, stemness, and EMT, as well as the downregulation of oncogenic pathways, such as cell cycle, mismatch repair, TGF-β, Wnt, and Notch signaling. Moreover, we found that ACE2 had a positive expression correlation with PD-L1, a predictive marker for an active response to immune checkpoint inhibitors. As a result, ACE2 upregulation correlates with a favorable response to anti-PD-1/PD-L1/CTLA-4 immunotherapy.

Our and others' studies indicate that ACE2 plays a protective role referin cancer, hypertension, heart disease, and COVID-19 patients. An intriguing phenomenon is that ACE2 as a SARS-CoV-2 human host cell receptor is crucial for SARS-CoV-2 to invade human cells, while its deficiency may exacerbate outcomes in COVID-19 patients [@b0040]. A potential explanation is that the ACE2 deficiency could worsen outcomes in the people with underlying conditions, such as hypertension, heart disease, and cancer, who are infected with COVID-19. Thus, using ACE2 inhibitors for preventing and treating COVID-19 may not be an advisable strategy for individuals with certain underlying conditions, such as hypertension, heart disease, and cancers.

It should be noted that the negative correlation between ACE2 and cancer progression presented in this study is an association but not a causation. To prove their causal relationship, further experiments are necessary. This would be an important direction for further studies.

2. Conclusions {#s0045}
--------------

*ACE2* upregulation was associated with increased antitumor immunity and immunotherapy response, reduced tumor malignancy, and favorable survival in cancer, suggesting that ACE2 is a potential protective factor for cancer progression. Our data may provide potential clinical implications for treating cancer patients infected with SARS-CoV-2.
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